Biooutsource

Biosimilars have caused a revolution in the development of biologic drugs

Remsima Case Study: The importance of ADCC in assessing clinically relevant differences Authors: Dr. Daniel Galbraith, Chief Scientific Officer and Andy Upsall, Director of Technical Services – BioOutsource Ltd. The Regulatory Authorities Verdict “Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of┬áspeed to market and low cost; these are fundamental …